China-based E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, a joint venture between VivaVision Biotech and Betta Pharmaceuticals (SHE: 300558) focusing on autoimmune disease drug development, has entered into a licensing deal with compatriot firm Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380). Under the agreement, Joincare will acquire development and commercialization rights for E-nitiate’s QY101 inhaler in China, while E-nitiate retains the rights to develop the product as a skin cream for external use. Financial details of the transaction were not disclosed.
QY101: A Novel PDE4 Inhibitor for Autoimmune Diseases
QY101 is a novel phosphodiesterase 4 (PDE4) inhibitor under development to treat plaque psoriasis and atopic dermatitis. The drug has successfully completed a Phase II study in China, demonstrating good safety and efficacy profiles. This positive outcome positions QY101 as a potential treatment option for patients suffering from these autoimmune conditions.
Expanding Treatment Options in China
The collaboration between E-nitiate Biopharmaceuticals and Joincare Pharmaceutical is set to expand treatment options for autoimmune diseases in China. With Joincare’s expertise in pharmaceutical development and commercialization, and E-nitiate’s focus on innovative drug development, the partnership aims to bring QY101 to market, offering a new therapeutic choice for patients in need.-Fineline Info & Tech
